Ptc Therapeutics (PTCT) Share-based Compensation (2012 - 2026)

Ptc Therapeutics' Share-based Compensation history runs 15 years deep, the most recent figure standing at $23.4 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 29.68% year-over-year to $23.4 million; the TTM figure through Mar 2026 stood at $79.9 million (up 7.55% YoY), while the FY2025 annual figure was $74.5 million, changed 0.09% from the prior year.
• Share-based Compensation was $23.4 million for Q1 2026 at Ptc Therapeutics, up from $18.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $29.4 million in Q2 2023 to a low of $17.2 million in Q4 2024.
• Historically, Share-based Compensation has averaged $23.0 million across 5 years, with a median of $21.6 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Share-based Compensation slumped 36.22% in 2024, then gained 29.68% in 2026.
• A 5-year view of Share-based Compensation shows it stood at $27.3 million in 2022, then declined by 1.47% to $26.9 million in 2023, then slumped by 36.01% to $17.2 million in 2024, then rose by 7.42% to $18.5 million in 2025, then advanced by 26.48% to $23.4 million in 2026.
• The last three Share-based Compensation figures came in at $23.4 million (Q1 2026), $18.5 million (Q4 2025), and $19.4 million (Q3 2025), per Business Quant data.